The groundbreaking approach of the medication represents a major advance in the management of the condition. Unlike existing therapies, tirzepatide targets dual pathways – the GLP-1 hormone and glucose-dependent insulinotropic polypeptide (GIP) – providing greater blood sugar management and potential reduction in weight. Researchers are studyin